滨会生物已向港交所提交上市申请。华泰国际、招银国际和中银国际是本次上市申请的联席保荐人。 滨会生物是一家致力于癌症免疫疗法发现、开发和商业化的生物科技公司，专注于溶瘤病毒疗法。 滨会生物拥有五项处于不同开发阶段的产品，其中多项具有全球同类首创的潜力。 公司的核心产品BS001（OH2注射液）是一种基于II型单纯疱疹病毒（HSV-2）的溶瘤病毒候选药物， 能够选择性复制于肿瘤细胞并激活全身免疫。BS001是全球首个达到临床阶段并进入III期关键试验的以 HSV-2为骨架的溶瘤病毒候选药物，并已在中国进行黑色素瘤III期临床试验。 BS001获得了FDA的孤儿药资格认定（用于治疗III-IV期黑色素瘤和恶性胶质瘤）和快速通道资格认定 （用于治疗耐药性或进展性黑色素瘤）。在一项Ia/Ib期试验中，BS001显示中位总生存期延长至31.06个 月，客观缓解率为34.48%（耐药PD-1疗法的患者高达42.1%）。 公司由在肿瘤免疫学和溶瘤病毒学领域拥有逾30年经验的刘滨磊博士领导，他曾是FDA批准的溶瘤病毒 药物IMLYGIC®（T-VEC）研发团队的核心成员。 （文章来源：证券时报网） ...

在刘光伟看来，调节性T细胞获奖实至名归。在2018年癌症免疫治疗（免疫检查点抑制剂）获得诺奖 前，大家就在预测，调节性T细胞（Treg）、Car-T和免疫检查点抑制剂等都可能获得诺奖。最终免疫检 查点抑制剂获得诺奖。"这次颁奖前，大家还在预测，可能是Car-T获奖，最终却是调节性T细胞摘得桂 冠。虽然感到是意料之中，但确有小惊喜。"他说。 北京时间10月6日下午，诺贝尔奖委员会宣布将2025年诺贝尔生理学或医学奖颁发给美国分子生物学家 Mary E. Brunkow，美国免疫学家Fred Ramsdell和日本免疫学家Shimon Sakaguchi，以表彰他们"为外周 免疫耐受的发现"作出的突出贡献。 诺贝尔委员会指出，三位科学家的核心贡献在于发现了调节性T细胞（regulatory T cells、Treg）—— 这群数量稀少但至关重要的免疫细胞，如同人体免疫系统的刹车系统，能够精准抑制过度活跃的免疫反 应，防止其误伤健康组织。 北京师范大学生命科学学院教授刘光伟接受新京报记者采访，介绍了调节性T细胞相关研究进展和背后 的故事。 刘光伟说，调节性T细胞在机体内所占比例很少，但是在维持机体健康中非常重要。机 ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 T 细胞耗竭 （ T cell exhaustion ） 是一种功能减退状态，其特征为效应功能减弱以及抑制性受体表达增 加，这种状态由持续的抗原暴露和不利的微环境所导致。在癌症中观察到耗竭 T 细胞 （Tex） 无法清除恶 性细胞，这也是癌症患者对免疫疗法产生抗性的关键机制。 尽管 转录组学 分析为 T 细胞耗竭 （Tex） 细胞生物学提供了见解，但在不同生物体中，mRNA 丰度并不 总是蛋白质表达水平的可靠替代指标。之前的研究表明，无论功能状态如何，T 细胞中 mRNA 与蛋白质的 相关性都很差，并且转录后调控在 T 细胞分化和功能中具有重要意义。在此背景下，绘制 Tex 细胞的高分 辨率蛋白质组图谱将很有价值。 该耗竭程序产生异质性的 Tex 细胞群，其中 祖细胞耗竭 T 细胞 （Tprog） 细胞保留了干性和自我更新能 力，能够对免疫检查点阻断 （ICB） 疗法作出响应，并分化为具有细胞溶解能力的 中间耗竭 T 细胞 （Tint） 。相反， 终末耗竭 T 细胞 （Ttex） 细胞会随着时间的推移而累积，并且对免疫检查点阻断疗法 响应不佳。 此外，T 细胞耗竭还限制 ...

Company Overview - The company is a clinical stage biopharmaceutical firm focused on transforming the cancer immunotherapy field and developing an oral patient-friendly obesity treatment [5]. Market Opportunity - The company is addressing two large markets with significant unmet medical needs, indicating a strong potential for growth and investment [5]. Leadership and Experience - The company boasts a very experienced team with a proven track record in clinical development, which enhances its credibility and attractiveness to investors [5].

Core Viewpoint - Nxera Pharma has initiated a Phase 2a clinical trial for its investigational immunotherapy drug HTL0039732, targeting advanced solid tumors, following successful Phase 1 results [1][2][3] Company Overview - Nxera Pharma is a biopharma company focused on developing specialty medicines for unmet medical needs, with a strong presence in Japan and the broader APAC region [9][10] - The company employs approximately 400 people across key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul, and is listed on the Tokyo Stock Exchange [11] Clinical Trial Details - The Phase 2a trial will expand to four patient cohorts, including those with microsatellite stable colorectal cancer, gastric adenocarcinoma, clear cell renal cell carcinoma, and metastatic castration-resistant prostate cancer [6] - The trial is sponsored and managed by Cancer Research UK's Centre for Drug Development, with key investigators from the University of Cambridge and King's College London [5][8] Drug Mechanism and Efficacy - HTL0039732 is an oral small molecule EP4 antagonist that blocks signaling through the PGE2-type prostanoid receptor 4, enhancing the immune system's ability to detect and control cancer cells [4] - The Phase 1 trial demonstrated early efficacy, including two confirmed partial responses in distinct tumor types when combined with the checkpoint inhibitor atezolizumab [3][4] Future Prospects - The initiation of the Phase 2a trial is seen as a significant milestone in the development of HTL0039732, with expectations for further updates as the trial progresses [7]

Core Viewpoint - Nxera Pharma has initiated a Phase 2a clinical trial for its investigational immunotherapy drug HTL0039732, targeting advanced solid tumors, following successful Phase 1 results [1][2][3] Company Overview - Nxera Pharma is a biopharma company focused on developing specialty medicines for unmet medical needs, with a strong presence in Japan and the broader APAC region [9][10] - The company employs approximately 400 people across key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul, and is listed on the Tokyo Stock Exchange [11] Clinical Trial Details - The Phase 2a trial will expand to four patient cohorts, including those with microsatellite stable colorectal cancer, gastric adenocarcinoma, clear cell renal cell carcinoma, and metastatic castration-resistant prostate cancer [6] - The trial is sponsored and managed by Cancer Research UK's Centre for Drug Development, with key investigators from the University of Cambridge and King's College London [5][8] Drug Mechanism and Efficacy - HTL0039732 is an oral small molecule EP4 antagonist that blocks signaling through the PGE2-type prostanoid receptor 4, enhancing the immune system's ability to detect and control cancer cells [4] - The Phase 1 trial demonstrated early efficacy, including two confirmed partial responses in distinct tumor types when combined with the checkpoint inhibitor atezolizumab [3][4] Future Prospects - The initiation of the Phase 2a trial is seen as a significant milestone in the collaboration between Nxera Pharma and Cancer Research UK, highlighting the urgent need for novel immunotherapies [7][8]

Core Viewpoint - The article discusses the advancements in Allo CAR-NKT cell therapy as a promising treatment for renal and ovarian cancers, highlighting its potential to overcome limitations of traditional CAR-T therapies [2][3]. Group 1: Allo CAR-NKT Cells in Renal Cancer - Allo CAR-NKT cells, targeting CD70, show strong cytotoxicity against both primary and metastatic renal cell carcinoma (RCC) [8]. - The study indicates that these cells can effectively target the immunosuppressive tumor microenvironment (TME) and eliminate CD70+ host alloreactive T cells, enhancing treatment durability [10]. - The research supports the potential of Allo CAR-NKT cells as a next-generation off-the-shelf immunotherapy for metastatic RCC [10]. Group 2: Allo CAR-NKT Cells in Ovarian Cancer - Allo CAR-NKT cells demonstrate unique efficacy and safety advantages in treating ovarian cancer, addressing challenges such as tumor heterogeneity and immune evasion [15][16]. - The engineered Allo15 M CAR-NKT cells exhibit superior anti-ovarian cancer effects compared to traditional CAR-T cells, with mechanisms targeting both tumor cells and the TME [15]. - These cells have a lower incidence of cytokine release syndrome and do not induce graft-versus-host disease (GvHD), making them a safer option for patients [15][16].

Core Insights - Anaveon is a Swiss biotech company focused on developing IL-2 receptor agonists to enhance cancer immunotherapy by selectively activating CD8+ T cells and NK cells while inhibiting Treg cell activity [2][6] - The company was founded in 2017 as a spin-off from the University of Zurich by Andreas Katopodis and Onur Boyman, both of whom have extensive experience in immunology and drug development [2][8] Company Overview - Anaveon has developed a lead pipeline candidate, ANV600, which is a novel bispecific compound combining an IL-2Rβ/γ selective agonist with a non-blocking PD-1 targeting antibody [7] - The company is currently conducting an open-label Phase 1/2 clinical trial for ANV600 to evaluate its safety and anti-tumor activity in patients with relapsed or refractory advanced solid tumors [7] Product Development - Anaveon's IL-2 receptor agonist is engineered to selectively activate the IL-2Rβ/γ signaling pathway, enhancing the immune response while minimizing off-target effects [6][7] - Another pipeline candidate, ANV700, combines a non-blocking PD-1 targeting antibody with IL-21 PAC to increase the cytotoxicity of CD8+ T cells in the tumor microenvironment [7] Funding and Recognition - Anaveon completed a Series A financing round of CHF 35 million in 2019, led by Syncona, and a Series B financing round of CHF 110 million in 2021, led by Forbion, with participation from Cowen Healthcare Investments, Pfizer Ventures, and Pontifax [8] - The company was recognized in the 2022 TOP100 Swiss Startups list, highlighting its innovative potential and market prospects in the biotech sector [10]

Core Insights - Carolyn Bertozzi, a Nobel laureate and prominent scientist, emphasizes the parallels between music and science, highlighting the importance of collaboration and listening in both fields [2] - Bertozzi has made significant advancements in bioorthogonal chemistry, which has implications for cancer treatment, particularly in targeted imaging and drug delivery [2][5] - The collaboration with Henlius, a Shanghai-based biopharmaceutical company, aims to initiate the first human clinical trials for a new cancer immunotherapy in the coming year [3][6] Group 1: Scientific Contributions - Bertozzi's research focuses on the role of sialic acid on cancer cells, which helps them evade the immune system; her team developed an antibody drug to target and eliminate this disguise [5][6] - The concept of bioorthogonal chemistry allows for the modification of specific biomolecules without disrupting natural biological processes, enhancing the development of therapeutic drugs [6] - The new immunotherapy, named EAGLE, shows promise in treating high mutation cancers like melanoma and lung cancer, with successful tests in animal models [6][7] Group 2: Collaboration and Diversity - Bertozzi advocates for diversity in scientific research teams, believing that varied backgrounds enhance problem-solving and research priorities [7][8] - She emphasizes the importance of student contributions to research, stating that many of her significant ideas originated from her students [8] - The collaboration with Henlius represents a strategic partnership aimed at advancing cancer treatment through innovative therapies [3][6]

Core Viewpoint - The article highlights the significant breakthroughs in cancer treatment through the work of Carolyn Ruth Bertozzi, particularly in the field of bioorthogonal chemistry, which enables targeted imaging and drug delivery for cancer cells, potentially revolutionizing cancer immunotherapy [4][6][8]. Group 1: Breakthroughs in Cancer Treatment - Carolyn Bertozzi's research focuses on the role of sialic acid on cancer cells, which helps them evade the immune system. Her team developed an antibody drug that removes this "camouflage," making cancer cells more recognizable to immune cells [6][7]. - The concept of bioorthogonal chemistry, introduced by Bertozzi, allows for specific tracking and modification of biological molecules without disrupting natural processes, facilitating the development of effective cancer therapies [7][8]. - The collaboration with Henlius (Shanghai Henlius Biopharma) aims to initiate the first human clinical trials for a dual-function sialic acid enzyme fusion protein therapy next year [4][8]. Group 2: Importance of Collaboration and Diversity - Bertozzi emphasizes the value of diverse backgrounds in scientific research, sharing her experiences of recruiting students from various institutions and disciplines to enhance creativity and problem-solving [10][11]. - She acknowledges that many of her significant research ideas originated from her students, highlighting the importance of fostering an environment where innovative ideas can flourish [11]. Group 3: Personal Insights and Interests - Bertozzi expresses her passion for music, drawing parallels between music and science in terms of creativity and collaboration. She plays bass guitar and has formed a band with fellow scientists, showcasing her multifaceted interests [3][13][14]. - Her upbringing and family support played a crucial role in her scientific journey, as her father encouraged her and her sisters to pursue their interests in science despite societal stereotypes [10].